Iterum Therapeutics plc’s $80 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per share, for total gross proceeds of approximately $80 million.

The ordinary shares are listed on the NASDAQ Global Market under the symbol “ITRM.”

Guggenheim Securities, Needham & Company, Leerink Partners and RBC Capital Markets acted as underwriters on the offering.

Based in Dublin, Ireland, Iterum Therapeutics plc is a pharmaceutical company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous branded penem available globally.

The Davis Polk corporate team included partners Sophia Hudson (Picture) and Richard D. Truesdell Jr. and associate Martin Oberst. The tax team included partner Michael Mollerus and associate Alexander J. Hendin. The intellectual property and technology team included counsel David R. Bauer and associate Tilak Koilvaram. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Sophia Hudson – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Martin Oberst – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Alexander Hendin – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Tilak Koilvaram – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: RBC Capital Markets; Leerink Partners; Needham & Co.; Guggenheim Securities;


Author: Ambrogio Visconti